ELISA reagent characterization using advanced LC-MS methods
When using commercial or process-specific ELISAs for Host Cell Protein (HCP) impurity measurements, regulatory reviewers require a characterization of the suitability of the ELISA reagents to the specific product.
Our observation from running a vast number of projects is that frequent challenges in ELISAs are:
A) Low HCP coverage
B) ELISA not measuring abundant HCPs
C) lack of dilutional linearity
D) different HCP values obtained when using new ELISA reagents
2D PAGE analysis cannot answer these challenges; they require higher resolution analytical methods to provide detailed information about the HCP coverage.
This webinar will show you results from ELISA reagent characterization using advanced LC-MS techniques on various biologics and expression systems.
The analyses include:
- HCP Coverage analysis of early process sample using ELISA immunocapture combined with mass spectrometry (ELISA-MS)
- Coverage of individual HCPs of potential concern
- Coverage of individual HCPs in the purified drug substance
- Comparison of the HCP standard with the early process sample
- Evaluation of high-responding HCPs and non-specific binding likely leading to lack of dilutional linearity
- Evaluation of cross-reactivity to the drug substance
Such a comprehensive ELISA reagent characterization enables a detailed understanding of the HCP-ELISA reagents and documentation of their suitability to the specific manufacturing process and purified drug substance. The LC-MS analyses also help bridge between ELISA reagents and explain differences in HCP measurements between old and new reagents.
Sign up below:
Date: 28 June 2023
Time: 16.30 CEST | 7.30am PDT | 10.30am EDT
Ejvind Mørtz, PhD
Co-Founder & COO, Alphalyse, Denmark
Ejvind holds a PhD from the University of Southern Denmark in Protein Chemistry & Molecular Biology. He has more than 20 years of experience developing protein analyses and mass spectrometry methods in the research & development of protein biologics; vaccines, monoclonal antibodies, therapeutic proteins, and cell and gene therapies.
Talk to us
Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.